Ribomunil
Ribomunil: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Use in childhood
- 10. Drug interactions
- 11. Analogs
- 12. Terms and conditions of storage
- 13. Terms of dispensing from pharmacies
- 14. Reviews
- 15. Price in pharmacies
Latin name: Ribomunyl
ATX code: LO3AX
Active ingredient: Ribosomal proteoglycan complex with antigens of typical bacteria
Producer: Pierre Fabre Medicament Production (France)
Description and photo update: 05.11.2017
Ribomunil is a drug of bacterial origin, a stimulant of nonspecific and specific immunity.
Release form and composition
Dosage forms:
- Tablets: round biconvex, almost white or white, odorless (12 or 4 pcs. In blisters, 1 blister in a cardboard box);
- Granules for preparation of oral solution: white, odorless (1 dose in a sachet, 4 sachets in a cardboard box).
Active components:
- Bacterial ribosomes titrated to 70% ribonucleic acid (including 3.5 shares of Klebsiella pneumoniae ribosomes, 3 shares of Streptococcus pneumoniae ribosomes, 3 shares of Streptococcus pyogenes ribosomes, 0.5 shares of Haemophilus influenzae ribosomes): 1 tablet - 0.25 mg or 0, 75 mg, in 1 sachet - 0.75 mg;
- Proteoglycans of the membrane part (including 15 shares of Klebsiella pneumoniae): in 1 tablet - 0.375 mg or 1.125 mg, in 1 sachet - 1.125 mg.
Excipients:
- Tablets: colloidal hydrophobic silicon, magnesium stearate, sorbitol;
- Granules: silicon, polyvidone, magnesium stearate, D-mannitol, sorbitol.
Pharmacological properties
Ribomunyl ensures the development of a specific and nonspecific immune response to infectious diseases of the ENT organs, which contributes to the emergence of antibacterial and activation of antiviral immunities. The drug has immunogenic and immunomodulatory properties, which indicates the ability of its active components to penetrate the intestinal mucosa.
Ribomunil contains the membrane fraction of Klebsiella pneumonia, which interacts with the receptors of the cells of the immune system, which are responsible for the development of innate immunity. These receptors are expressed by cells of the innate immune system, which leads to an increase in the activity of Ribomunyl in relation to a nonspecific immune response. The latter consists in enhancing the functional activity of neutrophils (adhesion and migration) and activating natural killer cells and monocytes / macrophages. Ribomunil also accelerates the maturation of human dendritic cells, which stimulates the proliferation of T cells, causing a specific response of the immune system to the ribosomal fractions of the drug.
Pharmacodynamics
Structural biochemical analysis proves the presence of macromolecules on the ribosomes belonging to the corresponding antigens, which are usually expressed on the walls of bacterial cells. Each ribosomal fraction is immunogenic due to the active interaction of RNA and ribosomal macromolecules. Its action is similar to that of a vaccine antigen and leads to the production of specific cells that synthesize antibodies in the mucous membranes and blood. These cells locally produce special antibodies that can discriminate between the antigens of the whole bacterial cell and reduce the adhesion of bacteria to epithelial cells.
Pharmacokinetics
Ribomunyl is characterized by good bioavailability. Its active components reach the intestinal Peyer's patches, where they stimulate the activity of immunocompetent cells.
The macromolecules contained in the drug do not participate in any special metabolic processes, therefore the probability of the drug entering into drug interaction is negligible.
Indications for use
The use of Ribomunil is indicated for the prevention and / or treatment of recurrent infections of the ear, nose, throat and respiratory tract, including in patients at risk:
- Otitis;
- Rhinitis, sinusitis;
- Laryngitis, pharyngitis, tonsillitis;
- Chronical bronchitis;
- Infectious bronchial asthma;
- Pneumonia;
- Tracheitis.
Contraindications
- Age up to 6 months;
- Autoimmune pathologies;
- Individual intolerance to the components of the drug.
Application during pregnancy and breastfeeding is possible if the expected effect of therapy for the mother is higher than the potential risk to the fetus or child.
Instructions for the use of Ribomunil: method and dosage
Tablets and granules are intended for oral administration, in the morning, before breakfast, once a day.
Before taking the granules, dissolve in boiled water at room temperature. It is advisable to prescribe granules to young children.
A single dose of Ribomunil for children and adults is 0.75 mg, which corresponds to 3 tablets of 0.25 mg, or 1 tablet of 0.75 mg, or 1 sachet of granules.
For treatment and / or prophylaxis, the drug is taken: within three weeks of the first month of therapy - 4 days in a row a week, then 5 months - in the first 4 days of each month.
Side effects
- Allergic reactions: rarely - urticaria, angioedema;
- Others: rarely - diarrhea, nausea, vomiting, at the beginning of use - a transient increase in the secretion of the salivary glands (hypersalivation).
Overdose
At the moment, no cases of drug overdose have been reported.
special instructions
According to the instructions, Ribomunil can cause a transient increase in temperature for two to three days, so patients should be warned about such a manifestation of the therapeutic effect of the drug. In addition, the development of transient minor symptoms of infections of the otorhinolaryngological organs is possible. Usually, these conditions do not require discontinuation of treatment.
The risk group includes long-term and frequently ill patients from 6 months to the elderly, including those with chronic pathologies of the respiratory organs. Prophylactic administration of the drug is carried out before the start of the autumn-winter season, especially in regions with unfavorable ecology.
The appointment of an immunomodulating agent as part of a complex therapy helps to increase the effectiveness and shorten the duration of treatment, significantly reduces the need for the use of antibiotics, bronchodilators, and prolongs the period of remission.
Childhood use
The use of Ribomunil for children is possible according to indications and according to the dosage regimen.
Drug interactions
Clinically significant drug interactions of Ribomunil have not been established.
Shows the simultaneous use of anti-inflammatory and bronchodilator drugs, antibiotics.
Analogs
There is no information on analogues of Ribomunil.
Terms and conditions of storage
Store at 15-25 ° C. Keep out of the reach of children.
Shelf life: 0.75 mg tablets and granules - 3 years, 0.25 mg tablets - 5 years.
Terms of dispensing from pharmacies
Available without a prescription.
Reviews about Ribomunil
Numerous reviews about Ribomunil from leading experts confirm the effectiveness of its use in pathologies of the upper respiratory tract. Clinical practice proves that even in the case of indolent and recurrent infectious diseases, prophylactic administration of the drug reduces the duration of the conservative course of treatment and ensures a quick recovery.
Many parents advise purchasing Ribomunil only in trusted pharmacies, as cases of drug counterfeiting have increased, which can negatively affect the health of the child.
Price for Ribomunil in pharmacies
On average, the price of Ribomunil in the form of tablets is 420-480 rubles (per pack, including 4 pcs.). Granules for preparation of oral solution can be purchased for 434–488 rubles (for a package consisting of 4 sachets).
Anna Kozlova Medical journalist About the author
Education: Rostov State Medical University, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes and does not replace the official instructions. Self-medication is hazardous to health!
